BioSyent Releases Financial Results for Q1 2024 financialpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialpost.com Daily Mail and Mail on Sunday newspapers.
Longer follow up and subset analyses from the pivotal FELIX Phase 2 data to be presented in oral presentations at ASCO and EHATwo patients enrolled in Phase 1 Systemic Lupus Erythematosus trial;.
Autolus Therapeutics plc: Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
17.05.2024 - MISSISSAUGA, Ontario, May 16, 2024 (GLOBE NEWSWIRE) - BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q1) ended March 31, 2024. Key highlights include: (CAD)Q1 2024% Change vs.Q1 2023Trailing .